How to Use Patient Case Studies in Regenerative Medicine Marketing

A regenerative medicine patient case study is a documented account of one patient's treatment, with the problem, the protocol, the measured outcome, the timeline, and the limits stated, published with that patient's written permission. Done well, it shows how you think and gives skeptical patients something checkable. Done badly, it works as an efficacy claim for a therapy that may not have regulatory approval for that use. This guide covers the consent you need, a template that keeps a case honest, how to deal with typicality, and when to hold a case back.

That is the short version. If you are still building the foundation around it, start with the clinical authority guide, which explains why evidence comes before the pitch. This guide goes deeper on the case study itself.

I market for independent, cash-pay practices, and regenerative medicine is the category where a single sentence on a case page can create the most risk. I am an engineer and marketer, so treat the rules below as an orientation to the sources I opened, and have your counsel review anything before it goes live.

Key Takeaways

• A case study can function as an efficacy claim. The FTC's health products guidance says testimonials and individual experiences do not substitute for scientific substantiation.
• FDA status shapes what you can imply. FDA's consumer alert says the only approved stem cell products are blood-forming stem cells from cord blood. It adds that exosome products intended to treat disease generally require approval.
• Get written permission before you publish. If you are a HIPAA covered entity, a valid authorization is the general rule for using patient information outside the permitted purposes.
• Use a fixed template. Baseline, protocol, measures, timeline, adverse events, and a typicality statement.
• Show the denominator. One strong result is a story. A result placed beside your own aggregate outcomes is evidence.

Why Case Studies Carry More Risk in This Category

Demand for regenerative care is high, and so is scrutiny. Patients arrive skeptical, and regulators watch the claims. A case study sits at the intersection, because it is persuasive by design.

FDA's consumer alert on regenerative medicine products, last updated in April 2024, states that the only stem cell products FDA has approved in the United States are blood-forming stem cells from cord blood. They are used for disorders affecting blood production. It says exosome products intended to treat diseases or conditions generally require approval and that none are currently approved. It also lists conditions for which no stem cell products are approved, including orthopedic, neurological, cardiovascular, and pulmonary conditions, and chronic pain.

What does that mean for a case study? Suppose your page describes a patient with knee osteoarthritis whose pain fell after an injection of a product FDA has not approved for that use. The page can then read as a claim that the product works for it. The regulatory status of your specific product and use is a question for your regulatory counsel, and the answer differs across therapies. I raise it because the case study format turns an implied claim into a vivid one.

Substantiation is the evidence an advertiser holds to support a claim at the time it is made. For health benefits, the FTC expects competent and reliable scientific evidence.

The FTC's Health Products Compliance Guidance says that an honest testimonial from an endorser is not enough on its own. It adds that testimonials do not constitute substantiation and that individual experiences are not a substitute for scientific research. It also says that health benefit claims typically need competent and reliable scientific evidence, which can mean randomized, controlled human clinical testing. That is the standard your case pages sit against.

None of this removes case studies from your toolkit. It changes what a good one looks like: it documents what happened, states limits, and points to the real evidence.

Three Permissions Before You Write

Before drafting, collect three separate permissions. I keep them on one checklist.

1. Authorization to use the patient's information. If you are a HIPAA covered entity, the general rule in 45 CFR 164.508 is that you may not use or disclose protected health information without a valid authorization. The rules carve out exceptions. A separate provision requires authorization for marketing uses, with narrow exceptions. A story with identifying details, a face, or a date and place is likely to identify a person. Whether you are a covered entity depends on your billing and electronic transactions, and state privacy laws may apply as well, so ask your counsel.
2. Consent to publish images and the story. The form should say where the material will appear, how long it will stay up, and that the patient can withdraw. The glossary entry on patient testimonials covers consent and claims in more depth.
3. Clinical review. The treating clinician confirms that every fact is accurate, that outcomes match the chart, and that the account matches what the patient was told at the time of consent to treatment.

Keep signed forms with the chart, with a log of publication dates and locations. If a patient withdraws, you need a way to find and remove every place the case appears.

Use a Fixed Case Study Template

A template keeps the writer honest and gives readers the same structure each time. It also makes your pages easier for search and AI systems to read, which the glossary calls extractability. Here is the template I recommend.

I spent 20 years as a software engineer and built my last app from zero to $500M. In software, a bug report without reproduction steps gets sent back. A case study without baseline, method, and follow-up deserves the same response, and that habit is why this template asks for measures before it asks for a story.

1. Summary. Two sentences: who, what problem, what was done, what was measured. Place it first so the section can stand alone.
2. Patient context. Age range, activity level, and relevant history, written so the person cannot be identified unless they have agreed to be named.
3. Presenting problem and prior care. The symptoms, how long they lasted, and what was tried before.
4. What was done. The protocol in plain language: the product or procedure, its source and preparation as you can state them accurately, the number of sessions, and the follow-up schedule.
5. How outcomes were measured. The instrument, such as a pain scale, a validated function score, or imaging, with baseline and follow-up dates.
6. Results and timeline. The measured change at each date, including any period without change.
7. Adverse events and what did not improve. Report both, or state that none were recorded in the follow-up period.
8. Where this case sits. Compare it with your typical patients on the same measure (see the next section).
9. Limits and evidence. State that one case cannot show cause and effect, and link to published research on the condition and the treatment, including research that finds little or no benefit. Visible sourcing like this supports your E-E-A-T signals.
10. Regulatory status. Describe in neutral terms how the product is regulated, if your counsel advises including it.

The Typicality Problem

Readers assume a case page shows what they can expect. The FTC's Endorsement Guides address this in 16 CFR 255.2: when an endorsement about a key attribute is likely to be read as typical, the advertiser should have adequate substantiation for that. If the advertiser lacks substantiation that the endorser's experience is representative, the advertisement should clearly and conspicuously disclose the generally expected performance in the depicted circumstances. The disclosure must also change the net impression so that the ad is not misleading.

The FTC's question-and-answer page on the Endorsement Guides adds that the guidance is not a safe harbor, and that whether something is deceptive depends on the facts. As I read it, a short phrase such as "results vary" does not tell a reader what to expect, so it is weak protection by itself. Your counsel can tell you what is adequate for your claims.

The practical answer is to publish your own typical results. That requires data you collect. If you track an outcome measure for every patient who receives a protocol, you can place one case next to your aggregate. For example, "Of the N patients treated with this protocol between [date] and [date], X completed follow-up. Of those X, A reported improvement on the [measure], B reported no change, and C reported worsening." Fill the placeholders only with figures from your own records, and state the follow-up rate.

Good Case Study, Weak Case Study

Use the right column as your review standard. The left column is the pattern that gives the category its reputation.

Show the Misses

Include patients who did not improve. A practice that publishes only wins looks selected, and skeptical readers notice. A page that includes a patient whose pain did not change, with what you did next, reads as honest and carries information that competitors rarely publish. Pages that add facts others lack give readers and AI systems something worth quoting, and your aggregate results and misses are exactly that.

Keep each miss as carefully de-identified as each success, and get the same permissions where an individual is identifiable.

When to Hold a Case Back

Some cases should not go live. Apply the five tests below.

• There is no follow-up. A result at two weeks tells a reader little about a condition that fluctuates.
• The only data is the patient's recollection. Add a measure first.
• The case implies a use FDA has not approved and your counsel is unsure. Wait for advice.
• The patient is in a vulnerable moment. A person newly diagnosed or in distress may not be in a position to give a free consent.
• The result is an outlier and you cannot show it. If you cannot place it beside your typical results, it misleads.

Holding a case back costs a page. Publishing the wrong one can cost far more.

Where to Publish and How to Structure It

Give each case a dedicated page with a descriptive title and a stable URL, and link each one from the condition page that fits it. Start the page with the summary, so a reader or an AI system can lift it. Link outward to the research you cite and inward to your condition and protocol pages. The structure follows the same logic as the regenerative medicine SEO guide, which covers how to build treatment and condition pages that hold up under scrutiny.

Mark up the page with accurate medical schema if your developer can do it correctly, and skip markup that restates claims you cannot support.

Review each case every six months. Update the follow-up, confirm links still work, and check that your claims match your current counsel's advice. Our glossary entry on content freshness explains why dated updates help.

Paid ads follow separate platform rules, which change. Before you reuse case content in an ad, read the platform's current health advertising policy yourself and ask your counsel. This guide does not cover those policies.

Your Next Step

Pick one past case that has follow-up data and send that patient a permission request this week, drafted with your counsel. One properly consented case is the proof that the rest of this guide builds on.

Questions practice owners ask

Can I publish patient testimonials in regenerative medicine? You can, with written permission and care. The FTC says honest testimonials alone do not substantiate a health claim, so a testimonial should describe the patient's experience and avoid implying that the treatment is established for a condition.

Do I need HIPAA authorization to publish a case? If your practice is a HIPAA covered entity, a valid authorization is the general rule for using patient information outside permitted purposes. Confirm your status and your state's rules with counsel.

What should a case study include? A summary, patient context, presenting problem, the protocol, how outcomes were measured, results with dates, adverse events, a comparison with your typical results, limits, and evidence.

Should I show patients who did not improve? Yes, as part of your aggregate results and in at least some individual cases. It supports trust and adds information other pages lack.

How many case studies do I need? Fewer, better cases beat a long list. Start with three on the conditions you treat most, each with follow-up and measures.

Action Checklist: Start This Week

1. Ask your counsel which of your products and uses FDA regulates as drugs or biologics.
2. Draft a patient authorization and image consent form with your counsel.
3. Pick the outcome measure for each protocol and record it for every patient from now on.
4. Choose three past cases with follow-up data and request permission.
5. Write each case with the ten-part template.
6. Compare each case with your aggregate results and write the typicality statement.
7. Have the treating clinician and counsel review before publishing.
8. Set a six-month review date for every case page.